A Pig Model of the Preterm Neonate: Anthropometric and Physiological Characteristics

A Pig Model of the Preterm Neonate: Anthropometric and Physiological Characteristics
复制标题

DOI:
10.1371/journal.pone.0068763
复制
发表时间:
2013-07-09
期刊:
影响因子:
3.7
通讯作者:
Lingwood, Barbara E.
Lingwood, Barbara E.
中科院分区:
综合性期刊3区
文献类型:
--
作者:
Eiby, Yvonne A.;Wright, Layne L.;Lingwood, Barbara E.

文献摘要

被引文献

相似文献

背景:大型动物模型是开发合理的早产儿临床新疗法的重要工具。我们提供了一个描述的新生猪作为一个模型的早产儿在生长参数,生理和需要在孕龄范围内的重症监护。方法:选取妊娠91 ~ 113d(足月115d) 6个时间点剖宫产29窝仔猪298头。两组在妊娠91天和97d时也接受母体糖皮质激素治疗。在这些时间点中的四个,在不同的实验方案中,使用标准的新生儿重症监护技术对仔猪(n = 79)进行通气、镇静和监测长达8小时。结果:体重由妊娠91d时的平均697 g (SD 193)增加到妊娠113d时的平均1331 g (SD 368)。妊娠第97d出生的仔猪在给予表面活性剂的呼吸支持下能够复苏并存活至少8小时。产妇在分娩前48小时和24小时接受糖皮质激素治疗可减少对呼吸机支持的需求,并改善心血管稳定性。结论:猪为人类早产生理学的研究和新治疗方法的研究提供了相关的模型。
Background: Large animal models are an essential tool in the development of rationally-based new clinical therapies for preterm infants. We provide a description of the newborn pig as a model of the preterm neonate in terms of growth parameters, physiology and the requirement for intensive care over a range of gestational ages.Methods: Twenty-nine litters of piglets (n = 298) were delivered by caesarean section at six timepoints during gestation from 91d to 113d (term = 115d). Two groups, at 91 and 97d gestation, also received maternal glucocorticoid treatment. At four of these timepoints, piglets (n = 79) were ventilated, sedated and monitored using standard neonatal intensive care techniques for up to 8 h in various experimental protocols.Results: Body weight increased from mean 697 g (SD 193) at 91d gestation to 1331 g (SD 368) at 113d gestation. Piglets delivered at 97d gestation were able to be resuscitated and kept alive for at least 8 h on respiratory support after surfactant administration. Maternal glucocorticoid treatment 48 h and 24 h hours prior to delivery reduced the requirement for ventilator support and improved cardiovascular stability.Conclusion: The pig provides a relevant model for the study of human preterm physiology and for investigation of novel therapies to improve outcomes.